Document is current
Any future updates will be listed below
-
Authors
Slingluff, Craig L https://orcid.org/0000-0002-6664-4373
Lewis, Karl D
Andtbacka, Robert
Hyngstrom, John
Milhem, Mohammed
Markovic, Svetomir N
Bowles, Tawnya
Hamid, Omid
Hernandez-Aya, Leonel
Claveau, Joel
Jang, Sekwon
Philips, Prejesh
Holtan, Shernan G
Shaheen, Montaser F
Curti, Brendan https://orcid.org/0000-0003-3948-2708
Schmidt, William
Butler, Marcus O
Paramo, Juan
Lutzky, Jose https://orcid.org/0000-0002-9503-2130
Padmanabhan, Arvinda
Thomas, Sajeve
Milton, Daniel
Pecora, Andrew
Sato, Takami
Hsueh, Eddy
Badarinath, Suprith
Keech, John
Kalmadi, Sujith
Kumar, Pallavi
Weber, Robert
Levine, Edward
Berger, Adam
Bar, Anna
Beck, J Thaddeus
Travers, Jeffrey B
Mihalcioiu, Catalin
Gastman, Brian
Beitsch, Peter
Rapisuwon, Suthee https://orcid.org/0000-0002-1389-925X
Glaspy, John
McCarron, Edward C
Gupta, Vinay
Behl, Deepti
Blumenstein, Brent
Peterkin, Joanna J
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01546571 at ClinicalTrials.govnct00297895 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
https://doi.org/10.1136/jitc-2021-003272
nct03553836 at ClinicalTrials.govDocuments that mention this clinical trial
The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients
https://doi.org/10.1016/j.ejca.2013.08.023
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
https://doi.org/10.1136/jitc-2021-003272
nct04099251 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9505
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
https://doi.org/10.1136/jitc-2023-007501
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
https://doi.org/10.1200/jco.23.02355
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
https://doi.org/10.1136/jitc-2021-003272
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Addendum 1: <i>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</i>
https://doi.org/10.1136/jitc-2023-006947add1
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).
https://doi.org/10.1200/jco.2023.41.16_suppl.9504
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
https://doi.org/10.1136/jitc-2021-003272
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
-
Funding
Funding for this research was provided by:
POLYNOMA
- License Information
